Analyst Price Targets — GH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 12:01 pm | — | Morgan Stanley | $185.00 | $160.36 | TheFly | Guardant Health price target raised to $185 from $175 at Morgan Stanley |
| August 4, 2026 11:09 am | — | Stephens | $195.00 | $158.83 | TheFly | Guardant Health price target raised to $195 from $170 at Stephens |
| August 4, 2026 10:51 am | — | Piper Sandler | $193.00 | $158.83 | TheFly | Guardant Health price target raised to $193 from $135 at Piper Sandler |
| July 31, 2026 2:10 pm | Dan Leonard | RBC Capital | $200.00 | $161.87 | TheFly | Guardant Health price target raised to $200 from $185 at RBC Capital |
| July 31, 2026 1:08 pm | — | RBC Capital | $210.00 | $161.00 | StreetInsider | Guardant Health (GH) PT Raised to $210 at TD Cowen |
| July 31, 2026 11:44 am | Daniel Arias | Stifel Nicolaus | $180.00 | $152.35 | StreetInsider | Guardant Health (GH) PT Raised to $180 at Stifel |
| July 31, 2026 11:13 am | — | Goldman Sachs | $210.00 | $152.35 | TheFly | Guardant Health price target raised to $210 from $185 at Goldman Sachs |
| July 31, 2026 10:11 am | Anthony Petrone | Mizuho Securities | $200.00 | $152.35 | StreetInsider | Guardant Health (GH) PT Raised to $200 at Mizuho |
| July 31, 2026 10:09 am | Mark Massaro | BTIG | $195.00 | $152.35 | StreetInsider | Guardant Health (GH) PT Raised to $195 at BTIG |
| July 31, 2026 9:06 am | — | Barclays | $200.00 | $152.35 | TheFly | Guardant Health price target raised to $200 from $150 at Barclays |
Latest News for GH
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary of one of the largest health…
You found a great company, then watched it double before you got round to buying.
Bamco Inc. NY bought a new stake in Guardant Health, Inc. (NASDAQ: GH) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 16,500 shares of the company's stock, valued at approximately $2,475,000. A number of other institutional investors have also modified their holdings
Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,080 shares of the company's stock, valued at approximately $912,000. A number of other institutional investors and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.